Important Review and Other Articles.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 43
- By:
- Publication type:
- Article
Works matching IS 17927919 AND DT 2019 AND VI 14 AND IP 2
Results: 48
1
2
Predicting ~1% Median 5-Year Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease (CVD).
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 43
- By:
- Publication type:
- Article
3
Meta-Analysis: Statin Therapy Produces Significant Reductions in Major Vascular Events Irrespective of Age, But There is Less Direct Evidence of Benefit Among Patients Older Than 75 Years Who Do Not Already Have Evidence of Occlusive Vascular Disease.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 43
- By:
- Publication type:
- Article
4
TRED-HF: Patients Who Have Recovered from Dilated Cardiomyopathy (DCM) Will Relapse Following Treatment Withdrawal/Until Robust Predictors of Relapse are Defined, Treatment Should Continue Indefinitely.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 43
- By:
- Publication type:
- Article
5
POET: In Patients With Left-Sided Endocarditis Who Were in Stable Condition, Changing to Oral Antibiotic Treatment Was Noninferior to Continued Intravenous (IV) Antibiotic Treatment.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 42
- By:
- Publication type:
- Article
6
PIONEER-HF: Among Patients With Heart Failure (HF) With Reduced Ejection Fraction (HFrEF) Who Were Hospitalized for Acute Decompensated HF, Initiation of Sacubitril-Valsartan Led to a Greater Reduction in NT-ProBNP Than Enalapril with Similar Rates of Worsening Renal Function, Hyperkalemia, Symptomatic Hypotension, and Angioedema
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 42
- By:
- Publication type:
- Article
7
AVERT Trial: Apixaban Conferred a Lower Rate of Venous Thromboembolism Than Did Placebo Among Intermediate-To-High-Risk Ambulatory Patients With Cancer Who Were Starting Chemotherapy, Albeit with a Higher Rate of Major Bleeding Episodes.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 42
- By:
- Publication type:
- Article
8
CASSINI Trial: In High-Risk Ambulatory Patients With Cancer, Rivaroxaban Did Not Result in a Lower Incidence of VTE or Death Due to VTE Over 6-Months/However, During the Pre-specified Intervention Period, Rivaroxaban Led to a Lower Incidence of Such Events, With a Low Incidence of Major Bleeding
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 42
- By:
- Publication type:
- Article
9
Meta-Analysis: SGLT2 Inhibitors (SGLT2i) Have Moderate Benefits on Major Adverse CV Events (MACE) Confined to Patients With Established Atherosclerotic CV Disease (CVD)/They Also Have Robust Benefits on Reducing Hospitalization for Heart Failure (HF) and Progression of Renal Disease Regardless of Existing CVD or a History of HF
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 42
- By:
- Publication type:
- Article
10
EMPA-REG OUTCOME Trial: Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
11
DECLARE-TIMI 58: In Patients With Type 2 Diabetes Who Had or Were at Risk for Atherosclerotic Cardiovascular (CV) Disease (CVD), Treatment With Dapagliflozin did not Change MACE Rate vs Placebo But Did Result in a Lower Rate of CV Death or Heart Failure (HF) Hospitalization, Reflecting a Lower Rate of HF Hospitalization
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
12
CARMELINA: In Patients With Type 2 Diabetes and Cardiovascular (CV) Disease and/or Kidney Disease, Linagliptin did not Affect the Risk of Heart Failure (HF) Hospitalization (hHF) or Other Selected HFRelated Outcomes.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
13
VITAL Trial: Supplementation With Vitamin D or ω-3 Fatty Acids did not Result in a Lower Incidence of Cancer or Cardiovascular Events Than Placebo.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
14
FOURIER Trial: Higher Lipoprotein(a) - Lp(a) Levels are Associated with Increased Risk of CV Events in Patients with CV Disease Irrespective of LDL Cholesterol/Evolocumab Reduced Lp(a) Levels, and Patients With Higher Baseline Lp(a) Experienced Greater Absolute Reductions in Lp(a) and Tended to Derive Greater Benefit from PCSK9 Inhibition
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
15
ODYSSEY Outcomes: The Price of Alirocumab Would Have to be Reduced Drastically to be Cost-Effective.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
16
CLEAR Harmony Trial: Over 52 Weeks, Bempedoic Acid Added to Maximally Tolerated Statin Therapy did not Lead to a Higher Incidence of Overall Adverse Events Than Placebo and Led to Lower LDL Levels.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
17
REDUCE-IT: In Patients With High Triglycerides Despite Use of Statins, the Risk of Ischemic Events, Including CV Death, was Lower in Those Who Received 2 g of Icosapent Ethyl bid Than Those Who Received Placebo.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
18
Influenza Vaccination in Heart Failure (HF) Patients: Reduces Risk of All-Cause and Cardiovascular (CV) Death/Frequent Vaccination and Vaccination Earlier in the Year Confers Larger Reductions.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
19
APOLLO Study: Patisiran May Halt or Reverse the Progression of Cardiac Manifestations of Hereditary Transthyretin-Mediated Amyloidosis (hATTR).
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
20
IABP-SHOCK II: IABP Had no Effect on All-Cause Mortality at 6-Year Follow-Up/Mortality is Still Very High, With 2/3 Dying Despite Revascularization.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
21
Meta-Analysis: Catheter Ablation of AF in HF Patients was Superior to Drug Therapy in Improving Mortality, HF Hospitalizations, LVEF, 6-Minute Walk Test Distance, Vo<sub>2</sub>max, and Quality of Life, with no Significant Increase in Adverse Events.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 39
- By:
- Publication type:
- Article
22
Noninvasive Electrophysiology-Guided Cardiac Radioablation: Reduced Ventricular Arrhythmia Burden With Modest Short-Term Risks/Reduced Antiarrhythmic Drug Use/Improved Quality of Life.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 39
- By:
- Publication type:
- Article
23
P<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc is a Better Prediction Tool for AF-Related Ischemic Stroke than CHA<sub>2</sub>DS<sub>2</sub>-VASc: Abnormal P-Wave Axis-an ECG Correlate of Left Atrial Abnormality-Improves Stroke Prediction in AF.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 39
- By:
- Publication type:
- Article
24
ECG Monitoring of Emergency Room (ER) Patients with Syncope: Serious Arrhythmia Was Often Identified Within the First 2h of ER Arrival for CSRS* Low-Risk Patients and Within 6h for CSRS Mediumand High-Risk Patients/Outpatient Rhythm Monitoring for 15 Days for Selected Medium-Risk Patients and All High-Risk Patients Discharged from the Hospital Should be Considered
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 39
- By:
- Publication type:
- Article
25
Takotsubo Syndrome (TTS) Registry: Cardiogenic Shock Occurs in 10% and Portends a Worse Prognosis.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 38
- By:
- Publication type:
- Article
26
PRIME Study: Among Patients With Secondary Functional Mitral Regurgitation (MR), Sacubitril/Valsartan Reduced MR to a Greater Extent Than did Valsartan.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 38
- By:
- Publication type:
- Article
27
Large Noncortical or Cortical Infarcts (LNCCIs) in AF Patients Even in Anticoagulated Patients: Most Brain Infarcts Observed are Clinically Silent & Associated With Worse Cognitive Function, Raising the Question of MRI Screening in AF Patients.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 38
- By:
- Publication type:
- Article
28
Observational Data Suggest that NOACs May be Effective for Prevention of Thromboembolism in Patients With Mitral Stenosis and Atrial Fibrillation.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 38
- By:
- Publication type:
- Article
29
In an Animal Model, Serial Magnetic Resonance Imaging May Identify Early Stages of Anthracycline-Induced Cardiotoxicity.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 38
- By:
- Publication type:
- Article
30
PRECISE-DAPT: The Risk of Bleeding Rather Than Ischemic Risk Should Determine the Duration of DAPT After PCI/Prolonging DAPT is Associated With a Reduction in Ischemic Events in Patients Undergoing Complex PCI Who are not at High Bleeding Risk (HBR), But Confers No Benefit in Those at HBR, Regardless of PCI Complexity
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 38
- By:
- Publication type:
- Article
31
Cardiac Amyloidosis (CA): In Patients With CA and Atrial Tachyarrhythmias Referred for Cardioversion, the Incidence of Atrial Appendage Thrombus is High Even Among Those who Have Received Anticoagulants.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 37
- By:
- Publication type:
- Article
32
Fingesture Study/Sudden Cardiac Death (SCD) in Women: Women More Likely to Experience Nonischemic SCD Than Men, With Primary Myocardial Fibrosis (PMF) a More Common Cause of Death Among Women Than in Men.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 37
- By:
- Publication type:
- Article
33
EVEREST II @ 1 Year: MitraClip in Secondary Mitral Regurgitation (SMR) is Associated With Acceptable Safety, Reduction of MR Severity, Symptom Improvement, and Positive Ventricular Remodeling.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 37
- By:
- Publication type:
- Article
34
STS/ACC TVT Registry: Compared With the Year Before, Non-CV Hospitalizations Increase in the Year Following TAVI/Only Hospitalizations for Heart Failure (HF) Decrease.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 37
- By:
- Publication type:
- Article
35
NOTION Trial: In Patients With Severe Aortic Stenosis at Low Surgical Risk, Rate of Structural Deterioration of Valves is Greater Within the First 6 Years After Surgical AVR Than TAVI, While Rates of Valve Failure, Endocarditis, and All-Cause Mortality are Low and Similar With Both Methods
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 37
- By:
- Publication type:
- Article
36
PARTNER 3: Among Patients With Severe Aortic Stenosis Who Were at Low Surgical Risk, the Rate of the Composite of Death, Stroke, or Rehospitalization at 1 Year Was Significantly Lower With TAVI With a Balloon-Expandable Valve Than With Surgery.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 36
- By:
- Publication type:
- Article
37
PARTNER 2: TAVI is Cost-Effective vs Surgical Aortic Valve Replacement (AVR) in Patients With Severe Aortic Stenosis at Intermediate Risk for the US Healthcare System by Providing Greater Quality-Adjusted Life Expectancy and Lower Long-Term Costs than AVR if Long-Term Data Demonstrate Comparable Late Mortality With TAVI and AVR
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 36
- By:
- Publication type:
- Article
38
First-in-Human Percutaneous Transseptal Balloon-Expandable Mitral Valve Placement in 10 Patients with Severe Mitral Regurgitation (MR) at High Surgical Risk: Feasible in All but 1 Case, and Safe at 30 Days.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 36
- By:
- Publication type:
- Article
39
Global Feasibility Study of Trans-Apical Mitral Valve Replacement (TMVR) in First 100 Patients: TMVR (Tendyne, Abbott) Eliminated MR in Nearly All Cases/1-Year Mortality 26% Among Survivors/Improved Functional Status and Quality of Life.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 36
- By:
- Publication type:
- Article
40
Long-Term TAVI Valve Function Seems Excellent, With no Increase in Gradient or Regurgitation at a Median of 5.8 Years, up to 10 Years, With Severe Structural Valve Degeneration (SVD) Occurring in<0.5% of Patients.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 36
- By:
- Publication type:
- Article
41
French TAVI Registry: Anticoagulation Decreases Valve Dysfunction but Increases Mortality.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 35
- By:
- Publication type:
- Article
42
PFO closure: Durable Efficacy Against Recurrent Ischemic Events for Over a Decade.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 35
- By:
- Publication type:
- Article
43
COMPASS-CABG Study: Compared With Aspirin or Rivaroxaban Alone, the Combination of Rivaroxaban and Aspirin Did Not Prevent Early Failure of CABGs but Reduced MACE, Consistent With Outcomes in the Overall COMPASS Trial.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 35
- By:
- Publication type:
- Article
44
French SCAD Study: the rs9349379 Allele of the PHACTR1/EDN1 Genetic Locus Lying on Chromosome 6q24 is the First Genetic Risk Locus for Spontaneous Coronary Artery Dissection (SCAD).
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 35
- By:
- Publication type:
- Article
45
SWEDEHEART Registry: Troponinemia is not Innocent and Demands Careful Workup.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 35
- By:
- Publication type:
- Article
46
An Undersized Stent Does Not Forgive.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 31
- By:
- Publication type:
- Article
47
No-Reflow Phenomenon: A Major Issue Concerning Revascularization in Acute Coronary Syndromes.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 27
- By:
- Publication type:
- Article
48
Carcinogenic Impurities in Generic Sartans: An Issue of Authorities' Control or a Problem with Generics?
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 23
- By:
- Publication type:
- Article